Clinical Trial Update: A Study of HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating HS-10342 in Chinese patients with HR+/HER2- advanced and/or metastatic breast cancer is in the study phase with status not s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hr-positive Breast Cancer

Drugs mentioned

• HS-10342

Snippet

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Conditions: HR+/HER2- Advanced and/or Metastatic Breast Cancer | Phase 2 | Status: UNKNOWN